Standards of care for treatment of recurrent glioblastoma—are we there yet?
Citations
773 citations
749 citations
645 citations
453 citations
Cites background from "Standards of care for treatment of ..."
...Furthermore, very few therapeutic options exist for recurrent disease since patients with prior temozolomide exposure have progression-free survival (PFS) rates at 6 months of 20%–40% regardless of chemotherapeutic intervention (eg, nitrosoureas, temozolomide rechallenge, or bevacizumab).(5,6,8) Thus, there is an urgent need for drug development in recurrent glioblastoma....
[...]
428 citations
References
16,653 citations
9,802 citations
6,018 citations
3,381 citations
"Standards of care for treatment of ..." refers background in this paper
...established in 2005, following the pivotal European Organization for the Research and Treatment of Cancer (EORTC)/National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial, where concurrent temozolomide (75 mg/m(2)/daily for up to 7 weeks) and radiotherapy followed by 6 maintenance cycles of adjuvant chemotherapy (150-200 mg/m(2) 5-day therapy every 28 days) led to improved progression-free survival (PFS) and overall survival (OS).(4) Improved survival in this trial was largely restricted to a subset of patients harboring promoter methylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase (MGMT)....
[...]
3,077 citations